Ovestin vaginal cream 1mg/g, 15g with applicator — Made in Germany — Free Delivery

Hormone replacement therapy for the treatment of lower genitourinary tract atrophy associated with estrogen deficiency.

Pre- and postoperative treatment of postmenopausal women with vaginal surgery.

As an aid in the diagnosis of doubtful cases of atrophic cervical smear.

Hypersensitivity to the active substance or any of the excipients of the preparation.

Established, transferred or suspected breast cancer.

Established or suspected estrogen-dependent malignant tumors (for example, endometrial cancer).

Vaginal bleeding of uncertain etiology.

Untreated endometrial hyperplasia.

Previous or existing venous thromboembolism (VTE) (deep vein thrombosis, pulmonary embolism).

Established thromboembolic disorders (for example, deficiency of protein C, protein S or antithrombin, see section "Peculiarities of use").

Active or recent thromboembolic arterial disease (eg, angina pectoris, myocardial infarction).

Acute liver disease or a history of liver disease after which liver function tests have not returned to normal values.

Porfiry.

active ingredient: estriol; 1 g of cream contains estriol 1 mg; excipients: octyldodecanol, cetyl palmitate, glycerin, cetyl alcohol, stearyl alcohol, polysorbate 60, sorbitan stearate, lactic acid, chlorhexidine, sodium hydroxide, water.

 Dosage and administration

Ovestin contains only estrogen, so it can be used both in women with a preserved uterus and in women after hysterectomy.

At the beginning of treatment or while continuing treatment of symptoms of estrogen deficiency in postmenopausal women, a low effective dose should be used for the shortest possible period of time (see section "Peculiarities of use").

With atrophy of the lower genitourinary tract:

1 dose per day for the first weeks (up to a maximum of 4 weeks), followed by a gradual decrease to a maintenance dose (for example, a maximum of 1 dose 2 times a week), depending on the degree of symptom reduction.

For pre- and postoperative treatment of postmenopausal women with vaginal surgery:

1 dose of the preparation per day for 2 weeks before surgery; 1 dose 2 times a week for 2 weeks after surgery.

As an aid for diagnosis when obtaining an atrophic picture of a cervical smear:

1 dose of the preparation every other day for a week before taking the next smear.

In case of missing the next dose, the preparation should be administered immediately after the mention, if this did not happen on the day of the next dose. In the latter case, the missed dose should not be administered, and treatment should be continued according to the usual regimen.

DO NOT administer 2 DOSES IN THE SAME DAY.

Ovestin cream must be inserted into the vagina using a calibrated applicator. Apply in the evening before bed.

1 dose of the preparation (applicator filled up to the ring mark) contains 0.5 g of Ovestinâ cream, which corresponds to 0.5 mg of estriol.

For women who are not on hormone replacement therapy or are transitioning from continuous use of a combination preparation for HRT, treatment with Ovestin can be started on any day. Women transitioning from a cyclic HRT regimen should begin treatment with Ovestin 1 week after completion of the cycle.